Navigation Links
New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion
Date:1/5/2011

ischemic attack, or systemic embolism, left ventricular dysfunction, age greater than or equal to 75 years, age greater than or equal to 65 years with either diabetes mellitus, history of coronary artery disease, or hypertension)(2) were enrolled in the study for two years with a minimum follow-up period of one year.(4) RE-LY enrolled a comparable number of patients in each stroke risk group,(5) providing a broad representation of patients with NVAF.

The RE-LY® trial utilized the established PROBE (prospective, randomized, open-label, blinded endpoint evaluation) clinical trial protocol,(4) which has been used in the previous trials of anticoagulation for stroke prevention in patients with AFib.(4)  A PROBE design may reflect the differences in the management of warfarin and PRADAXA in clinical practice.(4)

The primary endpoint of the trial was incidence of stroke (including hemorrhagic) and systemic embolism.(4) Safety endpoints included bleeding events (major and minor), intracerebral hemorrhage, other intracranial hemorrhage, elevations in liver transaminases, bilirubin and hepatic dysfunction and other adverse events.(4)

In the RE-LY® trial, all clinical outcomes were adjudicated in a blinded manner to minimize bias in assessment of outcomes for each treatment.(4)

About Atrial Fibrillation and Stroke

Atrial fibrillation, characterized by an irregular heartbeat, can cause blood clots to form in the heart that can travel to the brain and cause a stroke.(6)  An estimated 2.3 million Americans are living with atrial fibrillation,(7) and the prevalence is expected to increase to 5.6 million by 2050.(7) A large managed care database study showed that NVAF represents approximately 95 percent of all atrial fibrillation cases in the U.S.(7)  Atrial fibrillation increases the risk of stroke nearly five times(8) and is associated with up to 15 percent of all strokes in the U.S.(8) Atrial fibrillation impo
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New PLATO Sub-Analysis of CABG Patients Presented at ACC
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
4. New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Associations Scientific Sessions
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... --  Vittamed Corporation , a neurodiagnostics medical device company based ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, ... " Teo Forcht Dagi is an experienced ... venture capital," said Remis Bistras , President and CEO ... strategic, and entrepreneurial expertise to our Board." Dr. ...
(Date:8/29/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... that results in demyelination, axonal transection, and neurodegeneration. The ... by the immune system, which targets neurons within the ... disease in which the damage of the myelin sheath ...
(Date:8/29/2014)... -- Pixcelldata, the innovative Irish developer of ... major new deal with Dutch based eX-Path, global providers ... Marius Nap . The announcement was ... Pathology which is taking placing between August 30th and ... where Pixcelldata will demonstrate its innovative solution. ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2
(Date:8/30/2014)... (PRWEB) August 30, 2014 The Plastic ... in New Jersey and even in the U.S. to ... takes inches off of patients’ waists with deep-tissue heating. ... in small sections, Vanquish is more inclusive to target ... Patients lay comfortably under panels about one inch away ...
(Date:8/30/2014)... RB SEO Services, a well-recognized internet ... small businesses. , RBSEO Services knows this very well ... engine optimization service. So, the company has introduced this ... , On being asked about the service, a ... cost SEO service because many small businesses expressed their ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The ... the planet has been one of the main ... to create a positive impact around the world. ... staffed with top trained executives and trainers deliver ... people worldwide. Vital statistics demonstrate that significant ...
(Date:8/30/2014)... Acne is a common problem millions of American cope with ... a daily nuisance, for some, it can have a crippling impact ... lead to dramatic mood swings and depression. , Those struggling ... their skin. In some cases, that can make the problem even ... those on a quest for clearer skin can now view ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all ... Alzheimer’s Disease, Dementia, and Memory Loss . , Country ... being diagnosed with the Alzheimer’s, inspired Seniors Guide writers to ... The movie, out on October 14, 2014, shows a ... of the disease – which inspires a final tour from ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2
... Biosciences LLC, a Boston-based company conceived in partnership ... today that Johnson & Johnson has joined the ... will have the opportunity to invest in the ... to fundamentally transform drug discovery and development and ...
... Limited (Nasdaq: WCRX ) announced today that ... close on Tuesday, January 27, 2009. In addition to ... Executive Officer and Paul Herendeen, Executive Vice President and ... audio webcast to discuss the 2009 Financial Guidance for ...
... Keystone Symposium - Obesity: Novel Aspects of the Regulation ... Genetics, Inc. (NYSE Alternext US: ILI) announced today that ... role genetics play in an individual,s ability to lose ... during tomorrow,s Keystone Symposium titled, "Obesity: Novel Aspects of ...
... Blood Bank is honored to announce that it has ... of Cellular Therapy ("FACT"). CORD:USE is a leading ... processing, storage and distribution of donated cord blood. ... more than 14,000 patients with over 70 life-threatening diseases ...
... DIEGO, Jan. 22 Aero Financial, Inc, a strategic ... that the company has been retained as a strategic ... distributor of natural health information and nutrition products.Pursuant to ... Finest(TM) in several facets of the company,s growth plans, ...
... for 11:00 a.m. ET POWAY, Calif., Jan. 22 ... provider of diagnostic imaging products and services that improve ... before the market opens on Thursday, February 5, 2009, ... December 31, 2008. A conference call is scheduled for ...
Cached Medicine News:Health News:Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies 2Health News:Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies 3Health News:Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss 2Health News:Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss 3Health News:CORD:USE Cord Blood Bank Receives Prestigious Accreditation from the Foundation for the Accreditation of Cellular Therapy 2Health News:Aero Financial Retained as Strategic Consultant by Only Natures Finest(TM) 2Health News:Digirad Corporation to Release Fourth Quarter and Year-End Financial Results on February 5, 2009 2
... Ultralight Jarrod Goggles have set the ... Nonslip soft silicone saddle nose bridge. ... better and lasts longer. Adjustable elastic ... without breakable plastic strap clips. 0.75 ...
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
QualCraft™ Radiation Protection Eyewear providex maximum comfort and eye protection! Lenses made of 0.75 mm leaded glass. Side shields of 0.30 mm leaded acrylic help seal out scatter radiation ...
Portable shields for your safety and convenience....
Medicine Products: